Centene stock has delivered a very strong 136.8% return over the past year, yet the latest valuation checks still suggest the shares lean cheap rather than fully priced.

• Over the last 12 months Centene has returned 136.8%, which puts extra focus on whether today's buyers are paying too much for that rebound.
• Raised expectations for future revenue and earnings may support the current share price, while execution risks around Medicaid margin recovery and managed care profitability could still weigh on what investors are willing to pay.
• Centene screens as undervalued on most metrics, with 5 out of 6 valuation checks pointing to a share price that is still below what the broader fundamentals might justify.

The issue now is whether Centene's recent rally has already reflected the improved outlook, or if the current price still leaves a meaningful valuation cushion for new investors.

Is Centene Still Cheap on Sales?

P/S is often a useful yardstick for a large managed care company like Centene because revenue scale and pricing power tend to matter more than short term earnings swings. On this measure, Centene trades on a P/S of about 0.2x, compared with a Healthcare industry average of around 1.5x and a peer group average near 1.9x. That is a very wide gap for a stock that now sits on a much higher share price than a year ago.

The fair P/S ratio implied by the model is roughly 0.9x, which still sits well below the sector and peer benchmarks but far above the current 0.2x level. Even after the recent guidance lift for 2026 and the positive share price reaction, Centene still screens at a large discount to what the model suggests investors might normally pay for its size, margins and risk profile.

On the P/S multiple, Centene stock appears undervalued and trades well below both its tailored fair ratio and the wider Healthcare peer group.

The Centene Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where this Centene valuation puzzle leaves off. They spell out which assumptions about Centene's growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price on the Community page. Each narrative ties a specific fair value estimate to a clear story about Centene's possible catalysts and risks so you can track over time which version of events is actually unfolding.

Centene investors on the Community page are split between a sharp recovery story and a thesis that the recent rerating has already gone too far.

Bull case: 16% undervalued

"Ongoing digital transformation and AI-driven payment integrity initiatives are set to deliver structural cost reductions and superior medical loss ratio management..."

Bear case: 20% overvalued

"Rising government scrutiny over managed care costs and ongoing legislative focus on pricing transparency are set to intensify regulatory pressure on Centene..."

Do you think there's more to the story for Centene? Head over to our Community to see what others are saying!

The Bottom Line

Centene still screens as undervalued on market multiples, even after a strong 1 year run. The key question is whether that discount reflects lingering concern about Medicaid margins and managed care profitability, or a genuine gap between price and fundamentals that can close over time. For now, the valuation case hangs on whether Centene can deliver on margin recovery without fresh execution or regulatory setbacks that would justify the market's caution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.